SCHEMBL4058425

SCHEMBL4058425

Cc1cccc(Oc2ccccc2)c1[N+](=O)[O-]

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.58
TDP1 Q9NUW8 2/20 0.58
TSHR P16473 4/20 0.51
SMN1; SMN2 Q16637 5/20 0.47
TLR4 O00206 1/20 0.46
TLR2 O60603 1/20 0.46
MAPT P10636 4/20 0.46
NPSR1 Q6W5P4 3/20 0.46
ATM Q13315 1/20 0.46
CYP1A2 P05177 2/20 0.45
CYP2C9 P11712 2/20 0.45
CYP2C19 P33261 1/20 0.45
RAB9A P51151 1/20 0.45
TP53 P04637 1/20 0.45
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
TTR P02766 1/20 0.43
ALB P02768 1/20 0.43
THRB P10828 1/20 0.43
HPGD P15428 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22588264 0.85 ALDH1A1 (0.53) ALDH1A1TDP1TSHRSMN1; SMN2TLR4
SCHEMBL6229655 0.84 SMN1; SMN2 (0.56) ALDH1A1TDP1TSHRSMN1; SMN2MAPT
SCHEMBL6229156 0.83 ALDH1A1 (0.50) ALDH1A1TDP1TSHRSMN1; SMN2MAPT
SCHEMBL6228854 0.82 ALDH1A1 (0.49) ALDH1A1TDP1TSHRSMN1; SMN2MAPT
SCHEMBL6136134 0.81 TDP1 (0.51) ALDH1A1TDP1TSHRSMN1; SMN2TLR4
SCHEMBL11220314 0.81 TLR4 (0.47) ALDH1A1TDP1TSHRSMN1; SMN2TLR4
SCHEMBL1616513 0.80 ALDH1A1 (0.69) ALDH1A1TDP1TSHRSMN1; SMN2RAB9A
SCHEMBL1997338 0.80 TLR4 (0.46) TDP1SMN1; SMN2TLR4TLR2MAPT
SCHEMBL10482222 0.80 TLR8 (0.60) ALDH1A1TDP1SMN1; SMN2TLR4TLR2
SCHEMBL10822131 0.80 KMT2A (0.50) ALDH1A1TDP1TSHRSMN1; SMN2TLR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7495015-B2 Indazole derivatives and methods for using the same ROCHE PALO ALTO LLC (US) 2009-02-24 US disclosed
EP-1931631-A1 1- (1H- INDOL- 1-YL) -3- (METHYLAMINO) -1- PHENYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) Wyeth a Corporation of the State of Delaware (US) 2008-06-18 EP disclosed
WO-2007041023-A1 1- (1H- INDOL- 1-YL) -3- (METHYLAMINO) -1- PHENYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) WYETH (US) 2007-04-12 WO disclosed
EP-1147093-B1 SUBSTITUTED BICYCLIC DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER PROD INC (US) 2007-04-11 EP disclosed
US-20070072897-A1 Phenylaminopropanol derivatives and methods of their use WYETH (US) 2007-03-29 US disclosed
EP-1747202-A1 INDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM F.HOFFMANN-LA ROCHE AG (CH) 2007-01-31 EP disclosed
US-20050215595-A1 Indazole derivatives and methods for using the same ROCHE PALO ALTO LLC 2005-09-29 US disclosed
WO-2005085206-A1 INDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM F. HOFFMANN-LA ROCHE AG (CH) 2005-09-15 WO disclosed
US-20030186995-A1 Substituted bicyclic derivatives useful as anticancer agents PFIZER INC. 2003-10-02 US disclosed
US-6541481-B2 A quinazoline compound PFIZER INC 2003-04-01 US disclosed
US-20010034351-A1 Substituted bicyclic derivatives useful as anticancer agents KATH JOHN CHARLES (US) 2001-10-25 US disclosed
EP-1147093-A1 SUBSTITUTED BICYCLIC DERIVATIVES USEFUL AS ANTICANCER AGENTS Pfizer Products Inc. (US) 2001-10-24 EP disclosed
US-6284764-B1 ANTIPROLIFERATIVE AGENT PFIZER INC. 2001-09-04 US disclosed
WO-2000044728-A1 SUBSTITUTED BICYCLIC DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER PRODUCTS INC. (US) 2000-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072897-A1 Phenylaminopropanol derivatives and methods of their use COMT, PNMT, GLS ALDH1A1 391/4885TDP1 418/4885TSHR 2990/4885
US-20030186995-A1 Substituted bicyclic derivatives useful as anticancer agents CCNA1, MCL1, RCC1 ALDH1A1 393/4885TDP1 1225/4885TSHR 3785/4885
US-20050215595-A1 Indazole derivatives and methods for using the same MAPK1, MAP3K1, MAP3K7 ALDH1A1 1080/4885TDP1 1440/4885TSHR 1823/4885
US-20010034351-A1 Substituted bicyclic derivatives useful as anticancer agents CCNA1, MCL1, RCC1 ALDH1A1 393/4885TDP1 1225/4885TSHR 3785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.